Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Tresa M. McGranahan; Alipi V. Bonm; Jennifer M. Specht; Vyshak Venur; Simon S. Lo

doi:10.3390/cancers14205136

Cancers (Oct 2022)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Tresa M. McGranahan,
Alipi V. Bonm,
Jennifer M. Specht,
Vyshak Venur,
Simon S. Lo

Affiliations

Tresa M. McGranahan: Department of Neurology, Alvord Brain Tumor Center, University of Washington School of Medicine, Seattle, WA 98195, USA
Alipi V. Bonm: Virginia Mason Franciscan Health, Seattle, WA 98101, USA
Jennifer M. Specht: Division of Medical Oncology, Fred Hutchinson Cancer Center/University of Washington, Seattle, WA 98109, USA
Vyshak Venur: Department of Neurology, Alvord Brain Tumor Center, University of Washington School of Medicine, Seattle, WA 98195, USA
Simon S. Lo: Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA

DOI: https://doi.org/10.3390/cancers14205136
Journal volume & issue: Vol. 14, no. 20
p. 5136

Abstract

Read online

In the past 5 years, the treatment options available to patients with HER2+ breast cancer brain metastasis (BCBM) have expanded. The longer survival of patients with HER2+ BCBM renders understanding the toxicities of local therapies even more important to consider. After reviewing the available literature for HER2 targeted systemic therapies as well as local therapies, we present a simplified algorithm for when to prioritize systemic therapies over local therapies in patients with HER2+ BCBM.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords